IvelinRadkov
Johnson & Johnson (NYSE:JNJ) announced Saturday that its psoriasis candidate JNJ-2113 maintained high levels of skin clearance through year one as part of a long-term extension to its Phase 2b FRONTIER 1 trial.
Last month, citing previewed data, the pharma giant said JNJ-2113, an oral IL-23 receptor blocker, reached all the primary and secondary endpoints in FRONTIER 1 in adults with moderate-to-severe plaque psoriasis (PsO).
Announcing the first readout from the FRONTIER 2 trial, in which all patients received JNJ-2113 after the first 16 weeks in FRONTIER 1, J&J (JNJ) said results through week 52 were consistent with those from the prior study.
There were no new safety signals, and the drug’s tolerability profile was in line with findings from FRONTIER 1.
The company’s pivotal Phase 3 ICONIC for the candidate in PsO is currently underway in partnership with Protagonist Therapeutics (NASDAQ:PTGX).
Noting that FRONTIER 1 and FRONTIER 2 suggested the potential of JNJ-2113 in other IL-23-mediated diseases, J&J (JNJ) said it has begun a Phase 2b trial to evaluate the candidate in ulcerative colitis, a bowel disorder.